Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, Japan & Intercontinental | July 08, 2022 | July 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date July 08, 2022 · Filed July 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,381.2782 |
Ending reported balance
After 2022-07-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-08 · Exercise / conversion · Acquired 3,675 · Balance 103,056.2782 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2022. Row 2 · 2022-07-08 · Sale · Disposed 3,675 · Balance 99,381.2782 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2022. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $35.20 · Expires 2023-05-11 | Direct | 25,725 |
Reported balance
After 2022-07-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-08 · Exercise / conversion · Disposed 3,675 · Balance 25,725 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2020 Filed Jul 8, 2020 00:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 591 | $70.00 | $41,370.00 |
DisclosureSEC source: 0001225208-20-009651 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,792.1404 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| June 11, 2020 Filed Jun 11, 2020 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 11,649 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-008854 · doc4.xml · derivative · entry 5 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,204 Underlying: Common Stock · 11,649 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| June 11, 2020 Filed Jun 11, 2020 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,362 | $71.25 | $595,792.50 |
DisclosureSEC source: 0001225208-20-008854 · doc4.xml · nonDerivative · entry 4 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,220.7768 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $70.88 to $71.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 11, 2020 Filed Jun 11, 2020 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,287 | $72.42 | $238,053.41 |
DisclosureSEC source: 0001225208-20-008854 · doc4.xml · nonDerivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,582.7768 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.90 to $72.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 11, 2020 Filed Jun 11, 2020 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 84 | $72.59 | $6,097.56 |
DisclosureSEC source: 0001225208-20-008854 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,869.7768 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| June 11, 2020 Filed Jun 11, 2020 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 11,649 | $13.98 | $162,853.02 |
DisclosureSEC source: 0001225208-20-008854 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,953.7768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 18, 2020 Filed May 18, 2020 21:42 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,717 | $216.68 | $372,039.56 |
DisclosureSEC source: 0001225208-20-007962 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,434.9256 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 358 | $225.05 | $80,567.90 |
DisclosureSEC source: 0001225208-20-007585 · doc4.xml · nonDerivative · entry 4 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,151.9256 Read SEC document |
| May 11, 2020 Filed May 11, 2020 21:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,883 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-20-007420 · doc4.xml · derivative · entry 7 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,951 Underlying: Common Stock · 3,883 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 11, 2020 Filed May 11, 2020 21:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,820 | $219.03 | $836,694.60 |
DisclosureSEC source: 0001225208-20-007420 · doc4.xml · nonDerivative · entry 6 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,210.9256 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 11, 2020 Filed May 11, 2020 21:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 44 | $219.07 | $9,639.08 |
DisclosureSEC source: 0001225208-20-007420 · doc4.xml · nonDerivative · entry 5 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,030.9256 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 11, 2020 Filed May 11, 2020 21:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10 | $218.66 | $2,186.60 |
DisclosureSEC source: 0001225208-20-007420 · doc4.xml · nonDerivative · entry 4 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,074.9256 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 11, 2020 Filed May 11, 2020 21:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5 | $219.96 | $1,099.80 |
DisclosureSEC source: 0001225208-20-007420 · doc4.xml · nonDerivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,084.9256 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 11, 2020 Filed May 11, 2020 21:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4 | $218.75 | $875.02 |
DisclosureSEC source: 0001225208-20-007420 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,089.9256 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 11, 2020 Filed May 11, 2020 21:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,883 | $41.94 | $162,853.02 |
DisclosureSEC source: 0001225208-20-007420 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,093.9256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007585 · doc4.xml · derivative · entry 5 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,281 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.expiration_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,627 | $217.84 | $354,425.68 |
DisclosureSEC source: 0001225208-20-007585 · doc4.xml · nonDerivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,329.9256 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 355 | $217.84 | $77,333.20 |
DisclosureSEC source: 0001225208-20-007585 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,956.9256 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007585 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,374.9256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007343 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 1,200 shares Expires 2027-05-06 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 9,600 | $0.00 Strike: $218.04 | $0.00 |
DisclosureSEC source: 0001225208-20-007343 · doc4.xml · derivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2027-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007343 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,210.9256 F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 23:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,883 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-20-006422 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,834 Underlying: Common Stock · 3,883 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 23:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,911 | $212.99 | $833,003.89 |
DisclosureSEC source: 0001225208-20-006422 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,235.9256 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 23:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,883 | $41.94 | $162,853.02 |
DisclosureSEC source: 0001225208-20-006422 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,146.9256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| March 30, 2020 Filed Mar 30, 2020 23:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,883 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-20-005680 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,717 Underlying: Common Stock · 3,883 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| March 30, 2020 Filed Mar 30, 2020 23:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,948.4077 | $198.10 | $980,279.57 |
DisclosureSEC source: 0001225208-20-005680 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,182.7209 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| March 30, 2020 Filed Mar 30, 2020 23:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,883 | $41.94 | $162,853.02 |
DisclosureSEC source: 0001225208-20-005680 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,131.1286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| February 05, 2020 Filed Feb 5, 2020 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,650 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-20-001734 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,650 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| February 05, 2020 Filed Feb 5, 2020 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,650 | $227.31 | $1,056,991.50 |
DisclosureSEC source: 0001225208-20-001734 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,248.1286 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| February 05, 2020 Filed Feb 5, 2020 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,650 | $35.79 | $166,400.25 |
DisclosureSEC source: 0001225208-20-001734 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,898.1286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| January 06, 2020 Filed Jan 6, 2020 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,650 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-20-000573 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,650 Underlying: Common Stock · 4,650 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| January 06, 2020 Filed Jan 6, 2020 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,650 | $230.95 | $1,073,917.50 |
DisclosureSEC source: 0001225208-20-000573 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,248.1286 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| January 06, 2020 Filed Jan 6, 2020 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,650 | $35.79 | $166,400.25 |
DisclosureSEC source: 0001225208-20-000573 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,898.1286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 17:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,650 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-015494 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,300 Underlying: Common Stock · 4,650 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 17:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,650 | $238.56 | $1,109,304.00 |
DisclosureSEC source: 0001225208-19-015494 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,248.1286 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 17:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,650 | $35.79 | $166,400.25 |
DisclosureSEC source: 0001225208-19-015494 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,898.1286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| November 05, 2019 Filed Nov 5, 2019 22:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,650 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-014162 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,950 Underlying: Common Stock · 4,650 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| November 05, 2019 Filed Nov 5, 2019 22:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,650 | $234.83 | $1,091,959.50 |
DisclosureSEC source: 0001225208-19-014162 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,248.1286 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| November 05, 2019 Filed Nov 5, 2019 22:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,650 | $35.79 | $166,400.25 |
DisclosureSEC source: 0001225208-19-014162 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,898.1286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| October 04, 2019 Filed Oct 4, 2019 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,650 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-013208 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 4,650 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| October 04, 2019 Filed Oct 4, 2019 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,650 | $223.18 | $1,037,787.00 |
DisclosureSEC source: 0001225208-19-013208 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,248.1286 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| October 04, 2019 Filed Oct 4, 2019 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,650 | $35.79 | $166,400.25 |
DisclosureSEC source: 0001225208-19-013208 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,898.1286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| September 05, 2019 Filed Sep 5, 2019 23:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,650 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-012199 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,250 Underlying: Common Stock · 4,650 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| September 05, 2019 Filed Sep 5, 2019 23:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,650 | $222.06 | $1,032,579.00 |
DisclosureSEC source: 0001225208-19-012199 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,248.1286 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| September 05, 2019 Filed Sep 5, 2019 23:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,650 | $35.79 | $166,400.25 |
DisclosureSEC source: 0001225208-19-012199 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,898.1286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,650 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-010865 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,900 Underlying: Common Stock · 4,650 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,650 | $211.54 | $983,661.00 |
DisclosureSEC source: 0001225208-19-010865 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,248.1286 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,650 | $35.79 | $166,400.25 |
DisclosureSEC source: 0001225208-19-010865 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,898.1286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| July 05, 2019 Filed Jul 8, 2019 18:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,650 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-010100 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,550 Underlying: Common Stock · 4,650 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.